https://scholars.lib.ntu.edu.tw/handle/123456789/563616
標題: | Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study | 作者: | Hung C.-C. Wang C.-Y. SHAU-HUAI FU RONG-SEN YANG FEI-YUAN HSIAO |
公開日期: | 2018 | 出版社: | Springer London | 卷: | 13 | 期: | 1 | 來源出版物: | Archives of Osteoporosis | 摘要: | Summary: This nationwide cohort study examined the potential disease-modifying effect of anti-osteoporosis medication on hip osteoarthritis. The results revealed that the usage of anti-osteoporosis medication is not associated with decreased risk in undergoing total hip arthroplasty in patient with hip osteoarthritis. Purpose: This study aimed to assess the association between use of anti-osteoporosis medications (AOMs) and the risk of undergoing total hip arthroplasty (THA) in patients with hip osteoarthritis (OA). Methods: Using the 2008–2013 National Health Insurance Research Database, we identified patients who were first diagnosed as having hip OA. All identified patients were followed until THA, death of any cause, or December 31, 2013, whichever occurred first. All AOM exposures were divided into three categories: bisphosphonates use, non-bisphosphonates use, and no use of AOMs and assessed in a time-varying manners. The primary outcome was THA. The secondary outcome was the differences in the longitudinal utilization of NSAIDs between AOM users and non-users. Time-dependent Cox proportional hazards models were used to investigate the effect of AOM use on the risk of THA. Results: We identified 35,870 patients who were first diagnosed as having hip OA and had no history of AOM use between 2009 and 2012. Among them, 3162 and 1667 patients had their first prescription of bisphosphonates and other non-bisphosphonates AOMs during the follow-up period. Mean age of bisphosphonates users, non-bisphosphonates users, and non-users was 75.62, 76.84, and 67.39?years, respectively. Bisphosphonates or non-bisphosphonates users did not show significant change when compared to non-users in terms of risk of undergoing THA [adjusted hazard ratio (aHR) 0.972, 95% confidence interval (CI) 0.743–1.273; aHR 0.926, 95% CI 0.672–1.277]. Conclusion: Our results showed that the use of AOMs is not associated with decreased risk of THA in patients with hip OA. ? 2018, International Osteoporosis Foundation and National Osteoporosis Foundation. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054614944&doi=10.1007%2fs11657-018-0522-9&partnerID=40&md5=de131106e424232fd1b07b763716ce19 https://scholars.lib.ntu.edu.tw/handle/123456789/563616 |
ISSN: | 1862-3522 | DOI: | 10.1007/s11657-018-0522-9 | SDG/關鍵字: | alendronic acid; calcitonin; denosumab; ibandronic acid; parathyroid hormone[1-34]; raloxifene; zoledronic acid; bisphosphonic acid derivative; bone density conservation agent; aged; Article; cohort analysis; disease association; female; follow up; hip osteoarthritis; human; major clinical study; male; national health insurance; osteoporosis; outcome assessment; prescription; priority journal; retrospective study; Taiwan; chemically induced; complication; factual database; hip osteoarthritis; hip replacement; middle aged; osteoporosis; postoperative complication; proportional hazards model; risk factor; Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoporosis; Postoperative Complications; Proportional Hazards Models; Risk Factors; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。